Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Drops By 18.2%

VYNE Therapeutics Inc. (NASDAQ:VYNE) saw a significant drop in short interest in the month of December. As of December 15th, there was short interest totaling 482,674 shares, a drop of 18.2% from the November 30th total of 590,135 shares. Approximately 1.5% of the company’s shares are sold short. Based on an average daily trading volume, of 825,976 shares, the days-to-cover ratio is presently 0.6 days. Based on an average daily trading volume, of 825,976 shares, the days-to-cover ratio is presently 0.6 days. Approximately 1.5% of the company’s shares are sold short.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Baker BROS. Advisors LP acquired a new position in VYNE Therapeutics during the 3rd quarter worth $285,000. Acorn Capital Advisors LLC boosted its stake in shares of VYNE Therapeutics by 72.0% in the 1st quarter. Acorn Capital Advisors LLC now owns 785,938 shares of the company’s stock valued at $1,242,000 after buying an additional 328,968 shares during the period. Adage Capital Partners GP L.L.C. grew its position in shares of VYNE Therapeutics by 87.2% during the second quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock worth $1,063,000 after buying an additional 300,000 shares in the last quarter. Kennedy Capital Management LLC purchased a new stake in shares of VYNE Therapeutics during the second quarter worth approximately $942,000. Finally, Shay Capital LLC purchased a new stake in shares of VYNE Therapeutics during the third quarter worth approximately $165,000. 83.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on VYNE shares. Weiss Ratings restated a “sell (e+)” rating on shares of VYNE Therapeutics in a report on Wednesday, October 8th. Wall Street Zen upgraded VYNE Therapeutics to a “sell” rating in a research note on Saturday, December 20th. Three equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, VYNE Therapeutics currently has a consensus rating of “Reduce” and a consensus price target of $4.50.

VYNE Therapeutics Stock Performance

NASDAQ VYNE opened at $0.58 on Friday. The firm has a market cap of $19.31 million, a price-to-earnings ratio of -0.74 and a beta of 1.94. The firm has a 50 day simple moving average of $0.42 and a 200-day simple moving average of $0.58. VYNE Therapeutics has a one year low of $0.28 and a one year high of $4.30.

VYNE Therapeutics (NASDAQ:VYNE) last announced its earnings results on Thursday, November 6th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.02. VYNE Therapeutics had a negative net margin of 6,425.19% and a negative return on equity of 80.84%. The firm had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.13 million. Equities analysts predict that VYNE Therapeutics will post -0.97 EPS for the current fiscal year.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.